title: Harnessing immune responses in the tumor microenvironment: all signals needed.
abstract: An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
authors.affiliation: Authors' Affiliation: The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Dung T
authors.initials: DT
authors.lastname: Le
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Jaffee
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D019013:CD40 Antigens / Q000819:agonists*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019013:CD40 Antigens; C518149:selicrelumab